Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list.

TheFly reported on June 16 that Canaccord analyst Whitney Ijem increased the price target on RYTM to $151 from $143 while maintaining a Buy rating. The update followed a positive interim review from the Phase 2 study of setmelanotide in Prader-Willi syndrome (PWS). Canaccord highlighted continued BMI improvements with longer treatment exposure, with reductions reaching 3.06% at six months compared with 1.84% at three months. The firm also noted that 8 of 10 patients with moderate to severe baseline hyperphagia achieved a clinically meaningful reduction of at least 7 points on the HQ-CT assessment.

On June 15, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced new data presentations from ENDO 2026 highlighting results from its MC4R agonist programs in acquired hypothalamic obesity, Bardet-Biedl syndrome, and Prader-Willi syndrome. The company reported positive findings showing improvements in weight-related outcomes and hyperphagia across multiple patient populations. Data included long-term setmelanotide results in acquired hypothalamic obesity, real-world outcomes in BBS patients, and Phase 2 results in PWS. The findings supported the potential of MC4R pathway therapies to address rare neuroendocrine disorders with limited treatment options and demonstrated continued progress across RYTM’s development programs.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company developing precision medicines for rare genetic obesity and neuroendocrine disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.